Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-04-19
DOI
10.1186/s12967-016-0852-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure
- (2015) Max S. Schreuer et al. MELANOMA RESEARCH
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
- (2015) Simon Chang-Hao Tsao et al. Scientific Reports
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- Double-stranded DNA in exosomes: a novel biomarker in cancer detection
- (2014) Basant Kumar Thakur et al. CELL RESEARCH
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors
- (2014) M. F. Sanmamed et al. CLINICAL CHEMISTRY
- Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
- (2014) L. Peuvrel et al. JOURNAL OF NEURO-ONCOLOGY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- CirculatingBRAFV600Ein the Diagnosis and Follow-Up of Differentiated Papillary Thyroid Carcinoma
- (2013) C. Pupilli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma
- (2013) Sail Abusaif et al. MELANOMA RESEARCH
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
- (2012) Stephanie Du Four et al. EUROPEAN JOURNAL OF CANCER
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy
- (2010) Kim A. Margolin et al. SEMINARS IN ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now